Health ❯Healthcare ❯Pharmaceuticals

Clinical Trials

Weight Loss Drugs Drug Development Gene Therapy Alzheimer's Disease Major Depressive Disorder Drug Safety Phase 3 Studies Efficacy Studies Hypertension Pain Management Cardiovascular Health Tirzepatide HIV Prevention Monoclonal Antibodies DREAMM Trials Sickle Cell Disease Treatments Cardiovascular Drugs Schizophrenia Treatments Weight Loss Treatments Amgen Safety Concerns Obesity Treatment Opioid Crisis PURPOSE Trials Antibiotics Metabolic Diseases Cognitive Decline Treatments Gepotidacin Respiratory Diseases Chronic Obstructive Pulmonary Disease Baloxavir Marboxil Data Integrity Experimental Drugs Eli Lilly & Company Antiviral Drugs Orforglipron Treatment Guidelines Regulatory Affairs Semaglutide Mental Health Eli Lilly Duchenne Muscular Dystrophy Weight Loss Medications FDA Advisory Committee Epilepsy Treatments Lecanemab Obesity Treatments Cardiovascular Risk Randomized Controlled Trials Prostate Cancer Drug Heart Failure Rare Diseases Hypertension Treatment GLP-1 Agonists Hypertrophic Cardiomyopathy COPD Treatment Cancer Treatments Dupixent Cancer Treatment

Viking’s Oral Obesity Pill Shows Strong Weight Loss but High Dropouts, Triggering Stock Rout

Heavy discontinuation and gastrointestinal side effects raised doubts about its ability to challenge larger rivals in the pill race.

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Four-Year Lecanemab Study Shows Growing Cognitive Benefits and Stable Safety

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

FDA Advisers Recommend Against Approval of GSK’s Myeloma Drug Blenrep

AstraZeneca’s Baxdrostat Delivers Significant Blood Pressure Reductions in Phase 3 Trial for Resistant Hypertension

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

BMJ Reveals Data Flaws in Pivotal Ticagrelor FDA Approval Studies

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death

Duke's SBI-810 Shows Promise as Non-Opioid Painkiller in Preclinical Studies

Single-Dose Flu Drug Proven to Reduce Household Transmission by 30%

Leqembi Approved by European Regulators for Early-Stage Alzheimer's Treatment

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

FDA to Decide on First Twice-Yearly HIV Prevention Shot by June

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock